Success Metrics

Clinical Success Rate
87.5%

Based on 7 completed trials

Completion Rate
88%(7/8)
Active Trials
6(40%)
Results Posted
43%(3 trials)
Terminated
1(7%)

Phase Distribution

Ph early_phase_1
1
7%
Ph phase_1
3
20%
Ph phase_3
1
7%
Ph not_applicable
2
13%
Ph phase_2
5
33%

Phase Distribution

4

Early Stage

5

Mid Stage

1

Late Stage

Phase Distribution12 total trials
Early Phase 1First-in-human
1(8.3%)
Phase 1Safety & dosage
3(25.0%)
Phase 2Efficacy & side effects
5(41.7%)
Phase 3Large-scale testing
1(8.3%)
N/ANon-phased studies
2(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

87.5%

7 of 8 finished

Non-Completion Rate

12.5%

1 ended early

Currently Active

6

trials recruiting

Total Trials

15

all time

Status Distribution
Active(7)
Completed(7)
Terminated(1)

Detailed Status

Completed7
Active, not recruiting3
Recruiting3
Terminated1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
15
Active
6
Success Rate
87.5%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (8.3%)
Phase 13 (25.0%)
Phase 25 (41.7%)
Phase 31 (8.3%)
N/A2 (16.7%)

Trials by Status

active_not_recruiting320%
terminated17%
recruiting320%
completed747%
not_yet_recruiting17%

Recent Activity

Clinical Trials (15)

Showing 15 of 15 trials
NCT07466316Phase 3

A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)

Recruiting
NCT07718672Phase 2

Hotspot Stereotactic Ablative Radiotherapy Versus Traditional Stereotactic Ablative Radiotherapy for the Treatment of Early-Stage Non-Small Cell Lung Cancer

Not Yet Recruiting
NCT02276443Not Applicable

Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative

Active Not Recruiting
NCT06381154Phase 2

Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

Active Not Recruiting
NCT04929028Phase 2

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

Active Not Recruiting
NCT02689427Phase 2

Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer

Completed
NCT01202305

The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

Recruiting
NCT05873712Phase 2

Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome

Recruiting
NCT07343401

Sarcoidosis Immunotsuppressive Therapy and Lymphoma Development

Completed
NCT04185337Early Phase 1

Ultrasound-Guided Photoacoustic Imaging for the Detection of Metastases in Inguinal Lymph Nodes

Completed
NCT03426189

HIV Persistence in Lymph Node and Peripheral Blood

Completed
NCT02036918Phase 1

Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer

Completed
NCT00416455Phase 1

Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer

Completed
NCT01649791Not Applicable

Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia

Terminated
NCT00621452Phase 1

Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma

Completed

All 15 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
15